SELLAS Life Sciences

Update in progress

SLS (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

SELLAS Life Sciences Group is a late‑stage clinical biopharmaceutical company developing cancer therapies in the United States. Its lead candidate, galinpepimut-S (GPS), is a WT1‑targeted peptide immunotherapy, and SLS009 (tambiciclib) is a selective CDK9 inhibitor. The company collaborates with Merck to study GPS with pembrolizumab in a Phase 1/2 trial across multiple cancers, with GenFleet for GFH009, and with MSK for WT1 vaccine tech. HQ in New York.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive